Standard BioTools Inc. (LAB) Stock Price & Analysis
Standard BioTools Inc. (LAB) — MoonshotScore 21/100 (Weak band), calculated Nov 18, 2026. Price $0.57 (+5.67%), as of the Nov 18, 2026 trading session; market cap $225M.
Educational signal · not a buy or sell recommendation · How to read this
Standard BioTools Inc. · LAB · NASDAQ
Standard BioTools Inc. develops and sells instruments, consumables, and services for scientists and biomedical researchers. The company operates in the proteomics and genomics segments, providing platforms for protein and gene identification and analysis.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Standard BioTools (LAB)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Cheap, but weak quality and a strained balance sheet. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Strained; Valuation: Cheap; Growth Durability: Flat; Momentum: Slipping.
- quarterly revenue $19M (Q3 FY2026, quarter ended Sep 30, 2026)
- EPS beat 3 of the last 8 reports
- Altman Z -0.37 · Piotroski F 2
Holding back: weak fundamentals, balance-sheet strain
Helping: an attractive price
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 27 | Weak | |
| 26 | Weak | |
| 24 | Weak | |
| 24 | Weak | |
| 21 | Weak | |
| 21 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.57 | |
| Change on the day | +5.67% | |
| 52-week range | $0.57 – $1.72 | |
| Market capitalisation | $225M | — |
| Price / earnings (trailing) | 4.86 | |
| Shares traded on the day | 697.4K |
Price & events
Other perspectives
Council score for Standard BioTools (LAB): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 7, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Standard BioTools (LAB), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Standard BioTools Inc. (LAB) is listed on NASDAQ. It employs 387 people and is led by Michael Egholm. In Q3 FY2026 it reported revenue of $19M and net income of $13M. The market values it at $225M.
What do the latest results show for Standard BioTools (LAB)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $19M. Against analyst estimates the company has EPS beat 3 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $19M | $13M | $0.03 (diluted) |
| Q2 FY2026 | $20M | -$27M | -$0.07 (diluted) |
| Q1 FY2026 | $21M | -$45M | -$0.12 (diluted) |
| Q4 FY2025 | $24M | $19M | $0.05 (diluted) |
What are the financial strengths and risks for Standard BioTools (LAB)?
Short answer · as of
The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is weak fundamentals, balance-sheet strain. The distress and quality screens read Altman Z -0.37 · Piotroski F 2. Trailing ratios: ROE -7.5% · ROA -6.2% · current ratio 9.75 · earnings yield -14.1% · free-cash-flow yield -23.5%.
Data-derived red flags
- Listing risk — at $0.57 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Financial-distress signal — its Altman Z-Score of -0.37 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-7.5%) — the business is not currently generating profit on shareholder capital.
How does Standard BioTools compare with its peers?
Short answer
Standard BioTools's score ranks 4th of 4 in the bounded comparison shown, against 3 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1.12 Nov 18, 2026 | $75.1M | 45 5-pillar Nov 18, 2026 | |
| $20.65 Nov 18, 2026 | $432M | 34 5-pillar Nov 18, 2026 | |
| $1.57 Nov 18, 2026 | $11.5M | 29 5-pillar Nov 18, 2026 | |
| Standard BioTools (LAB) — this page | $0.57 | $225M | 21 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held LAB in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Viking Global | Andreas Halvorsen | Q3 2026 | 0.13% | $43.44M | Held, unchanged |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What Investors Ask About Standard BioTools (LAB)
These answers are editorial: 1 of these 9 answers is drawn from the LAB research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for LAB?
LAB carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Standard BioTools Inc. develops and sells instruments, consumables, and services for scientists and biomedical researchers.
Is LAB a good stock to buy?
Stock Expert AI does not rate LAB buy, sell or hold. Standard BioTools Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the LAB stock price today?
The last price recorded for Standard BioTools Inc. (LAB), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What does Standard BioTools Inc. do?
Standard BioTools Inc. develops, manufactures, and sells advanced tools for proteomics and genomics research. The company's key platforms, including SomaScan and CyTOF, enable scientists and biomedical researchers to analyze proteins and genes with high throughput and precision.
What are the key factors to evaluate for LAB?
Standard BioTools Inc. (LAB) holds a MoonshotScore in the low range. To weigh it, start with the trailing P/E under Price & valuation on this page. Not financial advice.
How frequently does LAB data refresh on this page?
LAB's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven LAB's recent stock price performance?
Standard BioTools Inc. (LAB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative technology platforms (SomaScan, CyTOF). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LAB overvalued or undervalued right now?
The trailing P/E of Standard BioTools Inc. (LAB) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of LAB?
Fractional-share availability for Standard BioTools Inc. (LAB) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 16 figures on this page — 8 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com